having a large number of specificities but tend to be enriched for a particular Ag, often following immunization or exposure to the Ag [2] . Importantly, in 1975 the advent of hybridoma technology permitted the isolation of B cell clones allowing for continued production of monoclonal Ab's [3] .
Thus, monoclonal Ab's are a single clone of Ab's thought as being superior to polyclonal Ab's due to their selectivity and specificity for single Ag's. Over the last forty years, exploitation of their F o r P e e r R e v i e w ability to specifically recognise, immobilise, destroy or clear such Ag's has seen both polyclonal and monoclonal Ab's transformed into diagnostic markers, laboratory tools and powerful therapeutics and prophylactics for human diseases [4] [5] [6] . These Ab's are usually of the IgG isotype due to their generalised function in vitro and relatively long half-life and superior effector function in vivo as opposed to that of the IgA and IgM isotypes which have more specialised functions.
Ab's have enjoyed great utility in numerous applications within research laboratories, diagnostic laboratories and in clinical settings [7] . Laboratory methods such as immunohistochemistry, immunofluorescence, western blot, immunoprecipitation, enzyme-linked immunoassay and flow cytometry that rely exclusively on Ab's are routine in most biomedical laboratories. In clinical settings, Ab's are useful diagnostic markers providing evidence of infectious disease status and immunisation efficacy. Additionally, polyclonal Ab preparations have long been used as therapeutic/prophylactic agents with immune globulin (IVIg) still in frequent use [8] . These applications of polyclonal Ab's rely on their specificity and sensitivity but it is becoming apparent that Ab's are not as entirely specific or selective as first envisioned. The hope was that much of the difficulty associated with the mixtures of Ab specificity found with polyclonal reactivity could be alleviated through the use of monoclonal Ab's [7] . Thus, many monoclonal Ab's are now available for laboratory assays, having replaced polyclonal Ab's and have become the fastest growing area in biotherapeutics with approximately 40 now approved by the United States'
FDA and Europe's EMA [9] .
Since the original description of mouse monoclonal Ab's in 1975 [3] the various methods for monoclonal Ab generation has amplified and the generation of numerous species of Ab's including human clones is now possible [9] . Recombinant Ab's, where the genes encoding a monoclonal Ab are expressed in vitro, are now becoming a dominant form of Ab production. It is relatively simple to produce recombinant Ab's in a variety of expression systems such as mammalian, bacterial, yeast, insect, or plant cells once the original B cell clone has been selected [10] , although glycosylation is known to vary and this may affect Ab functions [11] . Nevertheless, the use of F o r P e e r R e v i e w recombinant monoclonal Ab's and traditional monoclonal Ab's has improved some of the unwanted reactivity profiles that have been associated with polyclonal Ab's, however monoclonal Ab's are not exempt from cross reactivity and some have the ability to bind to a variety of unrelated self or
foreign antigens through what is known as polyreactivity [12] . In fact, the term "Ab cross reactivity" suggests that each Ab binds to a primary epitope and that binding to any other epitope is an unwanted example of a lack of specificity. As summarized recently by Van Regenmortel [13] , a variety of mechanisms can explain how a polyspecific Ab can bind to multiple epitopes. Therefore, an Ab combining site, or paratope, may be a rigid structure but allow interaction with different epitopes at different subsites in a process called rigid adaptation [14] . Alternatively, Ab paratopes may adopt multiple conformations through flexibility and bind to many different epitopes via an induced fit mechanism [15] . Finally, according to the differential ligand positioning model, a flexible Ab structure can bind diverse epitopes at different regions of the Ab combining site [16] .
Together, these mechanisms can help explain the observed polyspecificity of numerous monoclonal Ab's and the fact that polyclonal antiserum can sometimes outperform certain monoclonal Ab's in specificity rankings.
In the current study, a recombinant monoclonal Ab to m-ras (anti-m-ras) was generated by immunization of a rabbit with an m-ras C-terminal peptide followed by isolation of a single rabbit peripheral blood B cell secreting specific IgG and recombinant expression of the rabbit Ab genes in mammalian cells. We were using this monoclonal Ab to study ras proteins, an important family of intracellular molecular switches with roles in the regulation of cell growth, survival and differentiation [17] . The most well-known of these are the p21 ras proteins h-ras, n-ras, and k-ras that are often mutated in human cancers and are highly homologous to ras family members r-ras, mras and rap and ral proteins [17] . Here we show that although the immunogen sequence used for immunization was specific to m-ras and the rabbit antisera and the recombinant anti-m-ras IgG bound to this peptide sequence somewhat specifically, upon further investigation it was found that the anti-m-ras IgG displayed cross reactivity. Thus, it bound both recombinant m-ras and the related 
Materials and Methods

Peptides and recombinant proteins
Polypeptides used for immunization and used as antigens in ELISA and array blot experiments were generated by solid phase synthesis and were a gift from Dr Ian Clarke-Lewis (Biomedical Research Centre, Vancouver BC, Canada). Recombinant human m-ras and h-ras used as antigens in ELISA experiments were produced in bacteria as GST fusion proteins and were a gift from Gary
Wilson (Biomedical Research Centre, Vancouver BC, Canada). The GST sequence was added to the N-terminus of m-ras and h-ras through the use of pGEX expression systems and was used as an affinity tag to purify the recombinant proteins using immobilized reduced glutathione and was not cleaved from the purified product [18] . The selected lymphocyte antibody method (SLAM) [20] was performed using peripheral blood lymphocytes from an immunized rabbit to isolate single rabbit B cells secreting IgG specific for mras. Antibody variable (V) region gene segments were cloned from a single cell as described previously [20] and expressed as rabbit IgG following insertion into mammalian immunoglobulin expression vectors [21] modified to contain rabbit IgG constant (C) region genes [22] . Rabbit IgG was isolated from culture supernatants of transiently transfected HEK293 cells as described [22] .
Immunisation of rabbits and antisera
The anti-m-ras V region cDNA sequences were obtained by Sanger sequencing of the Ig expression plasmids using a CMV promoter primer at the University of British Columbia NAPS unit (Vancouver, BC, Canada).
Enzyme-linked immuosorbent assay (ELISA)
ELISA was performed as described previously [22] . Briefly, flat bottomed 96-well microtiter plates (Nunc Maxisorp) were coated with peptides or recombinant protein at a concentration of 1 µg/ml in phosphate buffered saline (PBS) overnight at 4°C. The coating of different sized antigens at the same concentration will result in different densities of antigen depending upon their molecular weight and in-turn alters the binding curves obtained. Plates were then blocked with PBS containing 2% bovine serum albumin (BSA) at room temperature for 2 hours before addition of dilutions of rabbit antisera, culture supernatants containing rabbit IgG or affinity purified rabbit IgG. After an overnight incubation at 4°C the plates were washed with PBS containing 0.5% tween 20 (PBST) and the bound rabbit IgG detected with goat anti-rabbit IgG alkaline phosphatase (AP) conjugate for 1 hour at 37°C. Plates were washed again with PBST and developed using paranitrophenyl phosphate (pNPP) substrate with the optical density measured at 405nm in a spectrophotometer.
Peptide spot array blot
An overlapping peptide array corresponding to the primary amino acid sequences of human mras and h-ras was prepared by spotting peptides of 10 amino acid residues onto nitrocellulose 
Results
C-terminal regions of human m-ras and h-ras protein primary sequences were inspected for selection of peptides that displayed regions that could be exploited to generate m-ras specific Ab's.
Despite overall identity of 48.6% between human m-ras and h-ras, the C-terminal regions display much weaker identity ( Figure 1A) . Therefore, the region corresponding to amino acids 187-204 of human m-ras displayed just 21.7% identity to h-ras and was selected as being unique to m-ras ( Figure 1B ). Performing a NCBI Blast search using the 187-204 sequence of m-ras detected only mras protein sequences from a variety of species, including rabbit, but not to other related ras proteins. It was therefore hypothesized that this sequence might be an epitope capable of eliciting m-ras specific Ab's as the use of C-terminal peptides in immunization strategies results in Ab's that bind native protein [23] .
Antisera was obtained from a rabbit immunized with the synthesized peptide corresponding to residues 187-204 of m-ras which had been fused to the C-terminus of the tetanus toxoid epitope to promote immunogenicity in rabbits. ELISA was performed to determine binding specificity and titer of this antisera. As shown in Figure 2 , the rabbit antisera was very specific for the m-ras Peripheral blood B cells were then obtained from the rabbit to generate an m-ras specific monoclonal Ab by the selected lymphocyte antibody method (SLAM) [20] . Sheep red blood cells coated with the m-ras peptide were used to identify and isolate single rabbit B cells producing specific antibodies. The immunoglobulin V regions of one selected clone were amplified by PCR and cloned into immunoglobulin expression vectors [21] that contained rabbit C regions [22] to generate a rabbit IgG clone specific for m-ras. The antibody V region predicted amino acid sequences obtained from plasmid cDNA sequencing were aligned with the nearest rabbit germ-line V region segments as defined by IMGT/V-QUEST [24] . These amino acid sequences and junctional rearrangements are shown in Figure 3 . Analysis of the sequences revealed that the m-ras Vk sequence (Genbank accession number KX858713) was composed of the rearranged rabbit germline IGKV1S2*01 and IGKJ1-2*01 alleles with numerous somatic mutations clustered in the complementarity determining regions (CDR's) which also corresponded to predicted antigenbinding regions (ABRs) as determined by Paratome analysis [25, 26] (Fig 3A) . The m-ras Vh sequence (Genbank accession number KX858712) was composed of the rearranged rabbit germline IGHV1S69*01, IGHD8-1*01 and IGHJ4*01 alleles with evidence of CDR-focused somatic mutations. The Vh CDR3 in particular contained at least five somatic mutations that resulted in negatively charged aspartic acid residues (Asp, D) within the sequence. Further analyses of the Vh and Vk junctions indicated that there was also the likelihood of significant junctional insertions in CDR3 of both the m-ras Vh and the m-ras Vk regions (Fig 3B) .
The monoclonal rabbit anti-m-ras IgG was produced by transient transfection of HEK293 cells with plasmids pLC-rbCκ(m-ras) and pHC-rbCγ1(m-ras) that contain the genes for rabbit anti-m-ras kappa light chains and gamma1 heavy chains respectively. Rabbit IgG in culture supernatants was then tested for binding specificity by ELISA. Binding to several peptides corresponding to C- (ECPPSPEPTRKEKDKKGCHC) and h-ras (KLRKLNPPDESGPGCM) was first assessed.
Significant and specific binding of anti-m-ras IgG was observed to the m-ras peptide but not to peptides of r-ras2 and h-ras (Fig 4) . Control culture supernatant of untransfected HEK293 cells showed no binding to the m-ras peptide. Having confirmed that the anti-m-ras monoclonal IgG was specific for the m-ras C-terminal peptide, its ability to bind to recombinant ras proteins was next determined. Interestingly, we found that anti-m-ras rabbit IgG binds equally well to ELISA plates coated with m-ras or h-ras recombinant proteins (Fig 5A) , despite the latter protein not containing the immunogen epitope sequence. In other sandwich ELISA experiments to confirm these data, these ras recombinant proteins were first captured with the plate-bound anti-ras scFv Y13-259 [27] and then detected using the rabbit anti-m-ras monoclonal Ab. It was found again that both m-ras and h-ras were bound equally by the anti-m-ras monoclonal Ab (Fig 5B) even though a significantly weaker signal was detected to both proteins, possibly due to steric hindrance by the Y13-259 capture Ab.
Concerned about the specificity of the anti-m-ras monoclonal Ab, the potential epitopes of both m-ras and h-ras that bound the rabbit IgG were mapped using an overlapping peptide array corresponding to the primary amino acid sequences of human m-ras and h-ras. Supplementary are not bound despite containing positive charged residues. In addition, some peptides are bound strongly although they do not contain positively charged residues (e.g. h-ras peptide 22; m-ras peptides 21, 28 and 29). These data offer potential explanations in molecular terms as to how the anti-m-ras monoclonal Ab was able to bind to both m-ras and h-ras recombinant proteins. 
Discussion
Here we have investigated the polyspecificity of a recombinant monoclonal Ab originally selected for binding to an m-ras specific peptide sequence that was rich in positively charged amino acid residues. The initial aim was to identify an m-ras specific polypeptide sequence and to use this to raise an m-ras specific monoclonal Ab. However, we found that the anti-m-ras monoclonal IgG bound to both h-ras and m-ras polypeptides despite being selected for binding to an m-ras specific C-terminal peptide sequence and the rabbit antisera that this clone was derived from was very specific for the m-ras peptide. More detailed epitope analyses demonstrated that the anti-m-ras monoclonal IgG also bound to numerous linear peptide sequences within both the m-ras and h-ras primary sequences and that the majority of these peptides contained positively charged amino acid residues, partially explaining the Ab polyspecificity. This ability of a monoclonal Ab to bind numerous and diverse peptide sequences that we describe here highlight the role of the Ab combining site in providing a structural paratope that has the ability to recognize and bind many different epitopes, effectively expanding the Ab repertoire to allow recognition of any antigen. The results also demonstrate that the precise analysis of data obtained when using monoclonal Ab's for laboratory investigations involving protein detection is necessary as polyspecificity could give rise to numerous interpretations.
A common approach for generating antisera or monoclonal Ab's to a newly discovered protein, or to one where no suitable Ab reagents exist, is to immunize animals with a unique synthetic peptide found at the C-terminus of the primary sequence. This approach often results in specific Ab's that bind the native protein [23] and that have bioactivity in vivo [28] although cross reactivity or polyspecificity is rarely investigated. In this study we identified a C-terminal region of human mras that was unique amongst the known ras protein sequences and it was hypothesized that this sequence would elicit m-ras specific Ab's when used as an immunogen. In fact, we found that antisera obtained from animals immunized with the m-ras peptide bound the m-ras immunogen peptide much more strongly than it did to the corresponding h-ras peptide sequence that is only 21% F o r P e e r R e v i e w identical in primary sequence. Antisera binding to the h-ras peptide was detectable when undiluted but was lost at dilutions greater than 1:4 whereas binding to the m-ras peptide remained strong, even at antisera dilutions of 1:500. Thus, it was concluded that the antisera was "specific for m-ras"
and would be a useful starting point for monoclonal Ab development. Following selection of a monoclonal Ab from this pool of Ab's we found the Ab was capable of binding equally well to both the m-ras and h-ras polypeptides. Interestingly, the anti-m-ras monoclonal Ab did not display binding to the homologous lysine-rich peptide sequences of h-ras and r-ras2 whilst binding strongly to the m-ras immunizing peptide as shown in Figure 4 . These important results are suggestive of these peptides not being promiscuously sticky, at least in ELISA experiments, and that the Ab is also not a universal binder. Taken together, these findings reinforce the often observed phenomenon that with protein Ag's, polyclonal Ab's and antisera are almost always more specific than monoclonal Ab's. This is because protein Ag's contain multiple epitopes and that all Ab's to some degree are polyspecific, having the ability to bind to several and sometimes quite diverse epitopes.
Thus, a polyclonal mixture of Ab's will bind to numerous epitopes polyspecifically but the collective cross reactivity will be diluted out in such mixtures of Ab's due to the common specificity to an immunodominant epitope. This phenomenon does not readily occur with single monoclonal Ab's due to their selectivity for shorter epitopes and possible polyspecificity, theoretically explaining why polyclonal Ab mixtures often tend to be more specific than individual monoclonal Ab's [13] . Our data shows that, even though the polyclonal antisera can bind both the m-ras and h-ras peptides, it is much more specific for the m-ras peptide whereas the isolated monoclonal Ab from that mixture is far less selective, binding to numerous and diverse peptide sequences.
It is well established that the molecular interactions between Ab combining sites, which consists of six complementarity determining regions within the Ab Vh and Vl regions, and Ag epitopes are a series of weak noncovalent chemical bonds such as electrostatic interactions, hydrogen bonds, van der Waals forces, and hydrophobic interactions [29] . In addition, structural F o r P e e r R e v i e w considerations of both the Ab paratope and Ag epitope influence the strength and specificity of these interactions and can contribute to Ab cross reactivity and polyspecificity [30] . The data we have obtained for this monoclonal Ab suggest that electrostatic interactions between positively charged epitopes and a negatively charged Ab paratope may be an important factor in influencing the majority of polyspecific interactions and therefore the cross reactivity, although other interactions are also possible as not all peptides appeared to be bound via such electrostatic factors.
Thus, immunization with a peptide containing numerous (7 out of 18, 39%) positively charged amino acid residues resulted in selection of an Ab clone that preferred interactions with such residues. Although it was not anticipated that a preferential selection of Ab's that interact predominantly via these positive charges might occur, in hindsight it does seem likely, and could perhaps be exploited in the future to induce Ab polyspecificity via directed immunizations if desired.
Analysis of the anti-m-ras Ab V region CDR sequences revealed that 4 of the 6 CDR's (LCDR1, LCDR3, HCDR1, HCDR3) contained negatively charged amino acid residues that might interact with positively charged residues in the m-ras and h-ras epitopes. When looking at Ab paratopes, it is known that the HCDR3 contains the most diversity and forms the majority of contacts of Ab with Ag epitopes [31] . Interestingly the HCDR3 of the m-ras Ab contained numerous (5 out of 12, 42%) negatively charged amino acid residues that most likely resulted from somatic hypermutations brought about by positive selection through Ag binding. Furthermore, no positively charged amino acids were found in any of the 6 CDR's of the anti-m-ras Ab suggesting that these residues were selected against. Clearly, in the absence of structural data confirming the precise interactions between the Ab paratope CDR residues and the various epitopes it is pure conjecture that such electrostatic interactions dictate the Ab polyspecificity, however similar supporting observations have been shown previously with autoreactive monoclonal Ab's in mice [32] . Thus, our analyses of Ab V region sequences, coupled with the molecular observations of polyreactivity do help explain the molecular basis of the multispecificity of Ab's in general and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w specifically in this case, the ability of the anti-m-ras monoclonal Ab to bind numerous peptides of both m-ras and h-ras.
When our investigations were expanded to a larger number of peptides we found that the antim-ras IgG could bind to numerous unrelated sequences to the immunizing peptide sequence in addition to similar peptide sequences. The peptide sequences we investigated were based on the primary sequences of both m-ras and h-ras in an effort to understand how the monoclonal Ab was able to bind both of these proteins equally. As such, we did not investigate binding to unrelated peptide sequences although it can be argued that the homology of m-ras and h-ras is disparate enough to have provided enough diversity in the peptide sequences we analyzed and might reflect cross reactive binding to unrelated polypeptides. The most common feature of the epitopes bound, as outlined previously, was the cationic property of the peptides although other unrelated peptide sequences were also bound. Thus, a minority of peptides appeared to interact with the Ab in a manner other than through positive/negative charges, perhaps via primary sequence recognition, hydrophobicity, or even a structural basis. These data emphasize the likelihood that this particular monoclonal Ab is polyspecific with numerous detectable interactions occurring depending on the nature of the epitope. Thus, the anti-m-ras monoclonal IgG is capable of binding to numerous divergent peptide sequences but that the majority of these contain positively charged amino acid residues (K, R, and H), which perhaps not surprisingly, were also enriched in the m-ras immunizing peptide. These data also help explain in molecular terms how the monoclonal Ab was found to bind to both m-ras and h-ras recombinant proteins.
In this study we performed heterogeneous immunoassays where binding of Ab's in solution to the immobilized Ag/peptide were favored because a consistent approach in analyzing Ab's binding to multiple epitopes was required. These assays therefore serendipitously allowed the description of some molecular details of the monoclonal Ab polyspecificity. Our analysis of the reactivity profile was limited to binding to a related ras recombinant protein and linear peptide sequences contained within ras proteins, although there is significant sequence divergence that would allow for bind to targets in addition to the one designed for [34] . This may be due to polyspecificity but the issue is often not investigated deeply unless discovered by chance. Additionally, differences in Ab reactivity profiles exist when using different analytical techniques and applications. Clearly, some
Ab's prefer denatured targets to native configurations and others rely on fixing or chemical modifications for optimal specificity and perhaps even polyspecificty.
In summary, our data have described the multispecificity of a recombinant monoclonal Ab that was discovered by chance. In this case, the data are suggestive of Ab multispecificty being regulated to a large degree by electrostatic interactions between a negatively charged Ab paratope and positively charged epitopes. Future experiments beyond what is possible in the current manuscript that would prove this theory would involve mutagenesis studies of the acidic residues found in the anti-m-ras Ab to probe the polyspecificity profile and modifications of basic residues in specific h-ras peptides may to confirm that the molecular nature of the cross reactivity is predominantly due to positive-negative charge interactions. Although this is just one example of Ab multispecificity, the phenomenon can be generally applied to monoclonal Ab's and question current Diluted rabbit antiserum from an immunised rabbit was allowed to bind to plate-bound C-terminal m-ras peptide (KKKTKWRGDRATGTHKLQ) or the corresponding h-ras peptide (KLRKLNPPDESGPGCM) before bound rabbit IgG was detected. Diluted culture supernatants containing rabbit mAb derived from an immunised rabbit was allowed to bind to plate-bound C-terminal m-ras peptide (KKKTKWRGDRATGTHKLQ), r-ras2 peptide (ECPPSPEPTRKEKDKKGCHC) or the corresponding h-ras peptide (KLRKLNPPDESGPGCM) before bound rabbit IgG was detected. Control refers to untransfected culture supernatant binding to plate-bound C-terminal m-ras peptide. (A) Diluted purified rabbit mAb from an immunised rabbit was allowed to bind to plate-bound recombinant m-ras or to recombinant h-ras before bound rabbit IgG was assessed. (B) Recombinant h-ras and m-ras were captured with plate-bound scFv Y13-259 and diluted rabbit mAb (squares) or rabbit antisera (circles) added before bound rabbit IgG was assessed. Binding of anti-rabbit IgG (secondary Ab only) and anti-mras mAb followed by secondary Ab (anti-mras mAb) to h-ras peptides (upper) and m-ras peptides (lower). Numbering refers to peptide # and sequence shown in Supplementary Figure 1 . The primary sequence of h-ras is shorter so 91 peptides span this polypeptide whereas 99 peptides are required to span the entire m-ras polypeptide. The h-ras (upper) and m-ras (lower) primary sequences are displayed with the overlapping peptides used in Figure 6 and shown in Supplementary Figure 1 , represented by a line underneath. Binding of the anti-mras monoclonal IgG is represented as the relative spot intensity obtained (Fig 6) . Each bar represents the level of IgG binding to the peptide and is aligned to the first residue of the peptide on the x-axis i.e. for h-ras the first peptide with discernible binding was peptide 2 beginning with E, whereas for m-ras the first is peptide 4 beginning with P. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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